Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report) shares crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $0.05 and traded as high as $0.0523. Provectus Biopharmaceuticals shares last traded at $0.0523, with a volume of 250,800 shares traded.
Provectus Biopharmaceuticals Price Performance
The firm has a 50 day moving average price of $0.05 and a two-hundred day moving average price of $0.06.
Provectus Biopharmaceuticals Company Profile
Provectus Biopharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing investigational therapies for cancer and immune-mediated diseases. The company’s research is based primarily on rose bengal, a small-molecule compound that it has formulated for potential use in oncology and dermatology.
Provectus’s lead product candidate is PV-10, an intralesional formulation of rose bengal being investigated for the treatment of solid tumors, including melanoma and certain liver cancers.
Recommended Stories
- Five stocks we like better than Provectus Biopharmaceuticals
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
